New antibody drug aims to unleash immune system on Hard-to-Treat cancers
NCT ID NCT06380816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The study aims to find the safest dose, understand side effects, and see if the drug can shrink tumors, either alone or with other cancer treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guy's Hopsital
RECRUITINGLondon, SE1 9RT, United Kingdom
-
The Christie NHS Foundation Trust
RECRUITINGManchester, United Kingdom
-
The Newcastle upon Tyne Hospitals NHS Foundation Trust
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
NOT_YET_RECRUITINGSouthampton, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a simple blood test spot ovarian cancer before it starts?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?